

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231
Pithampur - 454775, Dist. Dhar
Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- investors@medicaps.comWeb site:- www.medicaps.com**MCL/SE/2023-2024****Date: 23rd May, 2023****Online filing at: www.listing.bseindia.com**

To,
The General Manager
DCS-CRD
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street Fort, Mumbai – 400001(M.H.)

BSE Scrip Code: 523144 ISIN: INE442D01010**Subject: Submission of Standalone and Consolidated Audited Financial Results of the Company as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for quarter as well as year ended on 31st March, 2023.**

Dear Sir/Madam,

This is in Continuation of our letter no. MCL/BM/SE/2023-2024 dated 15th May, 2023 regarding information of Board Meeting for consideration and approval of Audited standalone and consolidated Financial Results for the Quarter as well as financial year ended 31st March, 2023.

Pursuant to provisions of the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby enclosing the Standalone and Consolidated Audited Financial Results of the Company for the Quarter as well as Financial year ended on 31st March, 2023 duly approved by the Board of Directors of the Company at its meeting held on today i.e. Tuesday, 23rd May, 2023 together with Auditors Report thereon, Statement of assets and liabilities, cash flow statement and declaration by the Managing Director & Chief Financial Officer of the Company pursuant to second proviso of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further above results shall also be submitted in XBRL mode (Excel Template provided by Exchange) within 24 hours from the conclusion of Board Meeting.

The Results shall be uploaded on Stock Exchange website at www.bseindia.com and on the website of the Company at www.medicaps.com and extracts of the aforesaid results shall also be published in Hindi (vernacular) and widely circulated English Newspaper.

You are requested to please take on record the aforesaid Audited Standalone and Consolidated Financial Results along with Auditor's Report for your records and reference.

Thanking You,
Yours Faithfully,

FOR, MEDI-CAPS LIMITED

ALOK K. GARG
MANAGING DIRECTOR
DIN: 00274321

Encl.:- Audited Standalone and Consolidated Financial Results along with Auditor's Report for Quarter and year ended 31st March, 2023

*Corporate Office: 201, Pushpratna Paradise 9/5 New Palasiya,
Opposite UCO Bank Indore (M.P.) 452001
Contact No: 0731-4028148*

RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS

412, Arcade Silver 56, 1, New Palasia, Indore - 1

☎ Off. : 2541132, Mobile : 9039080380

E-mail : rawkaassociates@gmail.com, cprawka@gmail.com

Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI {Listing Obligations and Disclosure Requirements} Regulations, 2015, as amended ('Listing Regulations')

TO THE BOARD OF DIRECTORS OF MEDICAPS LIMITED

Report on the audit of the Standalone Financial Results

Opinion


We have audited the accompanying standalone quarterly financial results of Medi-Caps Limited (hereinafter referred to as the 'Company') for the quarter and year ended March 31, 2023 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- a) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b) give a true and fair view in conformity with the recognition and measurement principles Laid down in the applicable accounting standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023 and its profit, total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance



these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion. Our opinion is not modified in respect of this matter.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

'The Company's Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial results that give a true and fair view of the net profit including other comprehensive income, changes in equity and cash flows and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.




Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to these risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
4. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future



events or conditions may cause the Company to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The Statement includes the results for the quarter ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2023 and the published unaudited year to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations. Our opinion is not modified in respect of this matter.

Place: Indore

Date: 23-05-2023

UDIN: 23429040BGXBDL3898

For: Rawka & Associates

Chartered Accountants

FRN: 021606C



(Venus Rawka)

Partner

M. No.: 429040

RAWKA & ASSOCIATES

— CHARTERED ACCOUNTANTS —

412, Arcade Silver 56, 1, New Palasia, Indore - 1

☎ Off. : 2541132, Mobile : 9039080380

E-mail : rawkaassociates@gmail.com, cprawka@gmail.com

Independent Auditor's Report on the Quarterly and Year to Date Audited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI {Listing Obligations and Disclosure Requirements} Regulations, 2015, as amended ('Listing Regulations')

TO THE BOARD OF DIRECTORS OF MEDICAPS LIMITED

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date consolidated financial results of **MEDICAPS LIMITED** (hereinafter referred to as the 'Holding Company') and its subsidiary **MEDGEL PRIVATE LIMITED** (the holding company and its subsidiary together referred to as "the group") for the quarter ended March 31, 2023 and for the year ended March 31, 2023 ("Statement"), attached herewith, being submitted by the holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- A) Includes the results of The Holding Company and its Subsidiary.
- B) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- C) give a true and fair view in conformity with the recognition and measurement principles Laid down in the applicable accounting standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023 and its profit, total comprehensive income, changes in equity and its cash flows for the year ended on that date.



Basis for Opinion


We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion. Our opinion is not modified in respect of this matter.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The Holding Company's Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these Consolidated Financial Results that give a true and fair view of the net profit including other comprehensive income, changes in equity and cash flows and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing Consolidated Financial Results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of




accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to these risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
4. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, modify our opinion. Our conclusions are based on



the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Consolidated Financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The Consolidated Financial Statements includes the results for the quarter ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2023 and the published unaudited year to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations. Our opinion is not modified in respect of this matter.

Place: Indore

Date: 23-05-2023

UDIN: 23429040BGXBDM9041



For: Rawka & Associates
Chartered Accountants

FRN: 021606C

(Venus Rawka)

Partner

M. No.: 429040

MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1,PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

STANDALONE AND CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2023

(Amount in Lacs except EPS)

S.N.	Particulars	Standalone					Consolidated				
		Quarter Ended			Year Ended		Quarter Ended			Year Ended	
		3 Month Ended 31/03/2023	3 Month Ended 31/12/2022	Corresponding 3 months ended in the previous year 31/03/2022	Year ended March 31 2023	Previous Year ended March 31 2022	3 Month Ended 31/03/2023	3 Month Ended 31/12/2022	Corresponding 3 months ended in the previous year 31/03/2022	Year ended March 31 2023	Previous Year ended March 31 2022
(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)		
I	Revenue from Operation										
	(a) Net sales	0.00	0.00	0.00	0.00	0.00	1018.37	1093.33	1659.49	4857.75	6831.10
	(b) Other operating income	6.22	1.27	0.00	10.14	0.00	38.54	10.51	95.87	79.35	156.01
	Revenue from Operation	6.22	1.27	0.00	10.14	0.00	1056.92	1103.84	1755.36	4937.10	6987.11
II	Other Income	2.59	0.09	14.31	64.46	60.74	23.83	16.93	144.59	160.32	191.42
III	Total income (I+II)	8.81	1.36	14.31	74.60	60.74	1080.74	1120.77	1899.95	5097.42	7178.53
IV	Expenses										
	a) Cost of material consumed	0.00	0.00	0.00	0.00	0.00	484.82	411.23	734.20	2205.25	3004.63
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	-111.24	123.84	-81.69	85.21	6.43
	d) Employee benefits expense	5.71	6.03	4.58	23.27	45.13	221.52	190.28	218.44	768.92	771.01
	e) Finance costs	0.00	0.00	0.00	0.00	0.00	0.01	0.02	0.00	0.16	0.02
	f) Depreciation and amortisation expense	2.31	2.31	(7.08)	9.23	9.23	22.06	50.25	39.30	174.32	181.32
	g) Power Cost	0.02	0.19	0.00	0.21	0.00	61.53	36.81	83.01	216.22	328.63
	h) Freight Exp.	0.00	0.00	0.00	0.00	0.00	110.53	67.34	522.97	505.30	1163.33
	i) Other expenses	3.78	2.89	2.61	16.32	12.46	212.08	107.20	236.83	649.97	717.40
	Total Expenses (IV)	11.82	11.42	0.11	49.03	66.82	1001.31	986.97	1753.06	4605.35	6172.77
V	Profit / (Loss) before exceptional item & tax (III-IV)	-3.01	-10.06	14.20	25.57	(6.08)	79.43	133.80	146.89	492.07	1005.77
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit/ (Loss) before tax (V-VI)	-3.01	-10.06	14.20	25.57	(6.08)	79.43	133.80	146.89	492.07	1005.77
VIII	Tax expense										
	1) Current Tax	0.00	0.00	0.00	0.00	0.00	42.00	80.00	0.00	122.00	0.00
	2) Earlier year (excess)/Short provision for tax written back	0.00	0.00	0.00	0.00	0.00	0.00	183.58	0.00	183.58	0.00
	3) Deferred Tax	-0.14	0.00	1.44	-0.14	1.44	-0.14	0.00	1.44	-0.14	1.44
	Total Tax Expenses	-0.14	0.00	1.44	-0.14	1.44	41.86	263.58	1.44	305.44	1.44
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
X	Profit (Loss) for the period from continuing operations (VII-VIII)	-2.87	-10.06	12.76	25.71	(7.52)	37.58	(129.78)	145.45	186.63	1004.33
XI	Profit/(loss) from discontinued operations	-1.36	-3.98	4.14	-11.07	3.72	-1.36	(3.98)	4.14	-11.07	3.72
XII	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit/(loss) from Discontinued operations (after tax) (XI-XII)	(1.36)	(3.98)	4.14	(11.07)	3.72	-1.36	(3.98)	4.14	-11.07	3.72

XIV	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00							
XV	Profit/(loss) for the period (X+XIII)	(4.23)	(14.04)	16.90	14.64	(3.80)	36.22	(133.76)	149.59	175.56	1008.05
XVI	Other comprehensive income										
	(a) (i) items that will not be reclassified to statement of profit & loss	-1.38	19.25	6.44	-32.70	35.69	24.17	53.15	24.11	55.95	146.32
	(ii) Income tax on items that will not to be reclassified to statement of P&L	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P&L	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Other comprehensive income :	-1.38	19.25	6.44	-32.70	35.69	24.17	53.15	24.11	55.95	146.32
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	-5.61	5.21	23.34	-18.06	31.89	60.39	(80.60)	173.70	231.51	1154.37
XVIII	Profit or Loss Attributable to										
	Profit or Loss Attributable to owners of Parents	0.00	0.00	0.00	0.00	0.00	36.22	(133.76)	149.59	175.56	1008.05
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Total Comprehensive Income for the period Attributable to										
	Total Comprehensive Income for the period Attributable to owners of Parents	0.00	0.00	0.00	0.00	0.00	60.39	(80.60)	173.70	231.51	1154.37
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00						
XXI	Reserves excluding revaluation reserves	0.00	0.00	0.00	4863.75	4881.80	0.00	0.00	0.00	10610.14	10378.60
XXII	Earnings per equity share (for continuing operation)										
	a) Basic (Rs.)	-0.02	-0.08	0.10	0.21	(0.06)	0.30	(1.04)	1.17	1.50	8.05
	b) Diluted (Rs.)	-0.02	-0.08	0.10	0.21	(0.06)	0.30	(1.04)	1.17	1.50	8.05
	Earnings per equity share (for discontinued operation)										
	a) Basic (Rs.)	-0.01	(0.03)	0.03	(0.09)	0.03	(0.01)	(0.03)	0.03	(0.09)	0.03
	b) Diluted (Rs.)	-0.01	(0.03)	0.03	(0.09)	0.03	(0.01)	(0.03)	0.03	(0.09)	0.03
	Earnings per equity share (for discontinued and continuing operation)										
	a) Basic (Rs.)	-0.03	-0.11	0.13	0.12	(0.03)	0.29	(1.07)	1.20	1.41	8.08
	b) Diluted (Rs.)	-0.03	-0.11	0.13	0.12	(0.03)	0.29	(1.07)	1.20	1.41	8.08

DATE: 23.05.2023
PLACE: INDORE



For and on behalf of board of directors of
MEDI-CAPS LIMITED

(Signature)

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1,PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

AUDITED STANDALONE AND CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH 2023

The standalone and Consolidated Statement of Assets & Liabilities is as under:

Particulars	(Amount in Lacs)			
	Standalone		Consolidated	
	As at		As at	
	31-03-23	31-03-22	31-03-23	31-03-22
	Audited	Audited	Audited	Audited
I. Assets				
(1) Non-Current Assets				
(a) Property, Plant and Equipment	246.49	277.50	3076.73	3117.21
(b) Capital work-in-progress	0.00	0.00	0.00	24.34
(c) Goodwill	0.00	0.00	2814.15	2814.15
(d) Financial Assets	0.00	0.00	0.00	0.00
(i) Investments	4390.67	4390.74	648.73	371.76
(e) Other non-current assets	4.91	5.02	38.58	38.69
Sub Total - Non-Current Assets	4642.07	4673.26	6578.19	6366.15
(2) Current assets				
(a) Inventories	0.00	0.00	706.90	1184.97
(b) Financial Assets				
(i) Investments	806.90	976.83	2558.70	2695.65
(ii) Trade receivables	223.82	224.16	846.44	1007.19
(iii). Cash and cash equivalents	4.05	11.06	111.36	22.83
(iv) Bank balances other than (iii) above	0.00	67.61	0.00	952.66
(c) Other current assets	485.70	227.63	1797.05	805.60
Sub Total - Current Assets	1520.47	1507.29	6020.45	6668.90
Total Assets	6162.54	6180.55	12598.64	13035.05
II. EQUITY AND LIABILITIES				
EQUITY				
(a) Equity Share Capital	1247.00	1247.00	1247.00	1247.00
(b) Other Equity	4863.75	4881.80	10610.14	10378.60
Sub Total - Equity	6110.75	6128.80	11857.14	11625.60
LIABILITIES				
(1) Non-Current Liabilities				
(a) Financial Liabilities	0.00	0.00	0.00	0.00
(b) Provisions	0.00	0.00	58.87	45.34
(c) Deferred tax liabilities (Net)	43.98	44.13	43.98	44.13
Sub Total - Non-Current Liabilities	43.98	44.13	102.85	89.47
(2) Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	0.00	0.00	0.00	0.00
(ii) Trade payables	0.00	0.00	0.00	0.00
a) total outstanding dues of micro enterprises and small enterprises; and				
b) total outstanding dues of creditor other than micro enterprises and small enterprises;	0.00	0.05	282.94	1168.03
(iii) Other financial liabilities (other than those specified in item (b),	0.00	0.00	0.00	0.00
(b) Other current liabilities	7.81	7.57	233.71	151.95
(c) Provisions	0.00	0.00	0.00	0.00
(d) Current Tax Liabilities	0.00	0.00	122.00	0.00
Sub Total - Current Liabilities	7.81	7.62	638.66	1319.98
Total Equity and Liabilities	6162.54	6180.55	12598.64	13035.05

DATE: 23.05.2023
PLACE: INDORE



For and on behalf of Board of director of
MEDI-CAPS LIMITED

ABOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

Audited Consolidated Segmentwise Revenue, Results and Capital Employed for Quarter and year ended 31st March, 2023

S.No.	Segment Revenue	(Amount in Lakhs)				
		Quarter Ended			Year Ended	Year Ended
		3 Month Ended 31/03/2023	3 Month Ended 31/12/2022	Corresponding 3 months ended in the previous year 31/03/2022	Year ended March 31 2023	Previous Year ended March 31 2022
		Audited	(Unaudited)	Audited	Audited	Audited
1	Segment Revenue					
	Pharma Division	1,071.93	1,119.41	1,885.64	5,022.83	7,117.80
	Real Estate Division	8.81	1.36	14.31	74.60	60.74
	Other	0.00	0.00	0.00	0.00	0.00
	Net Sale/Income From Operations	1,080.74	1,120.77	1,899.95	5,097.43	7,178.53
2	Segment Results (Profit) (+)/ Loss (-) before tax and Interest					
	Pharma Division	82.45	143.89	132.69	466.66	1,011.87
	Real Estate Division	(3.01)	(10.06)	14.20	25.57	(6.08)
	Other	0.00	0.00	0.00	0.00	0.00
	Total	79.44	133.84	146.89	492.23	1,005.79
	Interest Income	0.00	0.00	0.00	0.00	0.00
	Interest Expenses	0.01	0.02	0.00	0.16	0.02
	Other Unallocable Expenditure net off	0.00	0.00	0.00	0.00	0.00
	Unallocable Income	0.00	0.00	0.00	0.00	0.00
	Profit Before Tax	79.43	133.80	146.89	492.07	1,005.77
3	Capital Employed					
	Segment Assets (A)					
	Pharma Division	12,434.15	12,390.31	12,861.34	12,434.15	12,861.34
	Real Estate Division	164.48	166.79	173.71	164.48	173.71
	Other	0.00	0.00	0.00	0.00	0.00
	Total (A)	12,598.64	12,557.10	13,035.05	12,598.64	13,035.05
	Segment Liabilities (B)					
	Pharma Division	741.50	760.36	1,409.45	741.50	1,409.45
	Real Estate Division	0.00	0.00	0.00	0.00	0.00
	Other	0.00	0.00	0.00	0.00	0.00
	Total (B)	741.50	760.36	1,409.45	741.50	1,409.45
4	Total Capital Employed (Segment Assets-Segment Liabilities)					
	Pharma Division	11,692.66	11,629.95	11,451.88	11,692.66	11,451.88
	Real Estate Division	164.48	166.79	173.71	164.48	173.71
	Other	0.00	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets-Segment Liabilities)	11,857.14	11,796.74	11,625.59	11,857.14	11,625.59


DATE: 23.05.2023
PLACE: INDORE



For and on behalf of board of director of
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435				
Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231				
Audited Standalone and Consolidated Cash Flow Statement for the year ended 31st, March, 2023				
(Amount in Lakhs)				
PARTICULARS	Standalone		Consolidated	
	For the Year Ended 31st March 2023	For the Year Ended 31st March 2022	For the Year Ended 31st March 2023	For the Year Ended 31st March 2022
	Audited	Audited	Audited	Audited
A. Cash Flow from Operating Activities				
Net Profit/(Loss) before Tax & Extraordinary Items	25.57	(6.08)	492.07	1005.77
Adjustment For:				
Depreciation	16.01	18.19	181.10	190.27
Dividend Income	0.00	0.00	(0.28)	0.00
Other Comprehensive Income	(32.70)	35.69	55.95	146.32
Profit/(Loss) from Discontinue Operation	(11.07)	3.72	(11.07)	3.72
Operating Profit before Working Capital Change	(2.19)	51.51	717.77	1346.07
Adjustment for Working Capital	0.00	0.00	0.00	0.00
(Increase)/ Decrease in Sundry Debtors	0.33	16.94	160.75	(368.53)
(Increase)/ Decrease in Inventories	0.00	4.94	478.08	(514.37)
(Increase)/ Decrease in Loans & Advances	(257.97)	(52.05)	(991.34)	(158.44)
Increase in Current Liabilities & Provisions	0.19	(116.43)	(667.80)	397.37
Cash Generated from Working Capital	(257.45)	(146.61)	(1020.32)	(643.97)
Cash generated from Operation	(259.63)	(95.08)	(302.55)	702.10
Net Income Tax Paid	0.00	0.00	305.58	0.00
Net cash Flow from Operating Activity	(259.63)	(95.08)	(608.12)	702.10
B. Cash Flow from Investing Activities				
Proceed from Sale/purchase of Fixed Assets	15.00	29.82	(116.28)	(279.35)
Purchase/Sale of Investment	170.00	71.15	(140.02)	(128.16)
Dividend Received	0.00	0.00	0.28	0.00
Net Cash used in Investing Activities	185.00	100.97	(256.02)	(407.51)
C. Cash Flow from Financial Activities				
Increase in Long term borrowing	0.00	0.00	0.00	0.00
Net Cash Used in Financial Activities	0.00	0.00	0.00	0.00
Net Increase in Cash and Cash Equivalents (A+B+C)	(74.63)	5.89	(864.14)	294.60
Cash & Cash Equivalents at the				
Beginning of the year	78.68	72.79	975.49	680.89
Closing of the year	4.05	78.68	111.35	975.49
Increase in Cash and Cash Equivalents	(74.63)	5.89	(864.14)	294.60
<p>Note: This Cash flow statement is belongs to Continue and Discontinue operation both</p>				
DATE: 23.05.2023			For and on behalf of board of director of MEDI-CAPS LIMITED	
PLACE: INDORE			 ALOK K GARG MANAGING DIRECTOR DIN : 00274321	

NOTES:

1. The above Standalone and Consolidated Audited Financial Results for the Quarter and Financial Year ended March 31, 2023 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors in their meeting held on May 23, 2023.
2. The statutory auditor of the Company have carried out an audit of the books of accounts for the financial year 2022-23 and issued an audit report with unmodified opinion on standalone and consolidated audited financial results for the Quarter and Financial Year ended on March 31, 2023, therefore the Company is not required to give statement of impact of audit qualification for audit report with modified opinion.
3. This above financial results have been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India (“SEBI”) and the Companies (Indian Accounting Standards) Rules, 2015 (“Ind-AS”) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
4. The above consolidated financial results includes the result of wholly owned subsidiary company i.e. *Medgel Private Limited*.
5. The Company has two reportable segments for the Consolidated Financial Statements which consists Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and same is enclosed with this result.
6. The standalone and consolidated statement of assets & Liabilities as at March 31, 2023 is annexed with the results along with cash flow statements.
7. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or re-casted wherever found necessary.
8. The aforesaid audited financial Results will be uploaded on the Company's website www.medicaps.com and will also be available on the websites of the Stock exchange i.e. www.bseindia.com for the benefit of shareholders and investors.
9. As it has been already disclosed that Company has discontinued its manufacturing activities, accordingly there is a loss from discontinue operations for the quarter/year ended March 31, 2023.
10. Description of Income & Expenditure of Discontinue operations

(Amount in Lacs)

	Particulars	3 Months	3 Months	Year
		Ended	Ended	Ended
		31.03.2023	31.12.2022	31.03.2023
I	Income from operations	0.00	0.00	0.00
II	Other Income	1.00	0.00	3.19
III	Total income (I+II)	1.00	0.00	3.19


IV	Expenses			
	a) Changes in Inventories of finished goods, & work in progress	0.00	0.00	0.00
	b) Employee benefits expense	0.00	0.00	0.00
	c) Finance Cost	0.00	0.00	0.00
	d) Depreciation expense	0.06	2.24	6.78
	e) Other expenses	2.30	1.74	7.48
	Total Expenses (IV)	2.36	3.98	14.26
V	Net Profit/Loss From Discontinue Operation	-1.36	-3.98	-11.07

DATE: 23.05.2023

PLACE: INDORE

For and on behalf of the Board of Directors of
MEDI-CAPS LIMITED




ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231
Pithampur - 454775, Dist. Dhar
Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- investors@medicaps.com

Web site:- www.medicaps.com

MCL/SE/2023-2024

Date: 23rd May, 2023

Online filing at: www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street Fort, Mumbai – 400001(M.H.)

Subject: Submission of declaration regarding unmodified opinion of the Auditors on Annual Audited Standalone and Consolidated Financial Results of the Company for the year ended 31st March, 2023 as per second proviso to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.

Ref: MEDI-CAPS LIMITED (BSE Scrip Code: 523144, ISIN: INE442D01010)

DECLARATION

Pursuant to Regulation 33(3) (d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, We the undersigned do hereby declare that in the Audit Report, accompanying the standalone as well as consolidated Annual Audited Financial results of the Company for the financial year ended on 31st March, 2023, the statutory auditor M/s. Rawka & Associates does not express any modified opinion(s)/Audit qualification(s)/or other reservation(s) and accordingly the statement on impact of audit qualification is not required to be given.

You are requested to please consider and take on record the same.

Thanking You,
Yours Faithfully,
For, MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN 00274321

HEMANT SETHI
CHIEF FINANCIAL OFFICER